|
|
|
|
The most common adverse clinical event was diarrhea,which rarely interrupted therapy.Treatment was stopped because of reversible abnormal liver function test results(five or more times the upper limits of normal) in 3%,30%and 24%of the patients who received placebo,velnacrine maleate (150mg),and velnacrine maleate(22mg),respectively.Velnacrine produces modest but significant benefits in patients with Alzheimer's disease. Velnacrine maleate(225mg)is more effective than 150 mg of velnacrine.Both dosages have acceptable safety profiles. |
|